Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05917860 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer

Study acronym: NeoADT-TULSA
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 10 of 19 entries
    • Publications: details revised at 19 of 21 entries
    • Study description expanded, about 4 words
  2. Trial status: Recruiting to Active, Not Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Dec 1, 2025 to Jan 31, 2026
    • Study completion date: Dec 31, 2030 to Jan 31, 2030
    • Start date: Oct 1, 2023 to Jul 18, 2023
    • Site details revised
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to Oct 1, 2023
    • Primary completion date: Jul 1, 2025 to Dec 1, 2025
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Clinical studies have shown that magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) of the prostate is safe and effective. In the TULSA procedure, prostate tissue is killed by heating with ultrasound. This clinical trial explores if adding drug therapy with Degarelix before TULSA has the potential to improve further the effectiveness of TULSA in the treatment of localized prostate cancer, especially for patients with more aggressive diseases.
Trial Details
NCT Number NCT05917860
Lead Sponsor Turku University Hospital
Conditions
(from sponsor)		 Localized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov